PURPOSE: The objective of the present study was to delineate the efficacy of tetrathiomolybdate (TM), a novel antiangiogenic anticancer agent, as a chemopreventative agent. EXPERIMENTAL DESIGN: Nulliparous Her2/neu transgenic mice were treated with water or TM for 180 days and observed for tumor development during treatment and for 180 days after treatment. Mammary gland composition and architecture were also observed following TM treatment of Her2/neu transgenic and normal FVB mice. RESULTS: At the 1-year follow-up, 86.7% of control and 40% of TM-treated Her2/neu mice had palpable mammary tumors with a median time to tumor development of 234 days (95% confidence interval, 202-279 days) for control and >460 days for TM-treated mice (P < 0.0005, n = 15). The mammary glands from TM-treated Her2/neu and FVB mice showed a blunted epithelial ductal branching system due to a significant decrease in the number of secondary branches and total number of differentiated mammary epithelial cells. Microvessel density in Her2/neu and FVB mammary glands was lowered by 65.6 +/- 6.2% and 50.9 +/- 4.5% (P < 0.005), respectively, following TM therapy, consistent with the antiangiogenic effect of TM. Lastly, TM treatment resulted in a 2-fold increase in the absolute number of aldehyde dehydrogenase-positive mammary stem cells in Her2/neu and FVB mammary glands. CONCLUSION: Taken together, these results strongly support that TM is a potent chemopreventative agent as a consequence of hypoplastic remodeling of the mammary gland through modulation of the mammary stem cell compartment.
PURPOSE: The objective of the present study was to delineate the efficacy of tetrathiomolybdate (TM), a novel antiangiogenic anticancer agent, as a chemopreventative agent. EXPERIMENTAL DESIGN: Nulliparous Her2/neutransgenic mice were treated with water or TM for 180 days and observed for tumor development during treatment and for 180 days after treatment. Mammary gland composition and architecture were also observed following TM treatment of Her2/neutransgenic and normal FVB mice. RESULTS: At the 1-year follow-up, 86.7% of control and 40% of TM-treated Her2/neumice had palpable mammary tumors with a median time to tumor development of 234 days (95% confidence interval, 202-279 days) for control and >460 days for TM-treated mice (P < 0.0005, n = 15). The mammary glands from TM-treated Her2/neu and FVB mice showed a blunted epithelial ductal branching system due to a significant decrease in the number of secondary branches and total number of differentiated mammary epithelial cells. Microvessel density in Her2/neu and FVB mammary glands was lowered by 65.6 +/- 6.2% and 50.9 +/- 4.5% (P < 0.005), respectively, following TM therapy, consistent with the antiangiogenic effect of TM. Lastly, TM treatment resulted in a 2-fold increase in the absolute number of aldehyde dehydrogenase-positive mammary stem cells in Her2/neu and FVB mammary glands. CONCLUSION: Taken together, these results strongly support that TM is a potent chemopreventative agent as a consequence of hypoplastic remodeling of the mammary gland through modulation of the mammary stem cell compartment.
Authors: M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel Journal: J Natl Cancer Inst Date: 1999-11-03 Impact factor: 13.506
Authors: Michael I Koukourakis; Costantinos Manolas; George Minopoulos; Alexandra Giatromanolaki; Efthimios Sivridis Journal: Int J Surg Pathol Date: 2003-01 Impact factor: 1.271
Authors: J Cuzick; J Forbes; R Edwards; M Baum; S Cawthorn; A Coates; A Hamed; A Howell; T Powles Journal: Lancet Date: 2002-09-14 Impact factor: 79.321
Authors: Bruce G Redman; Peg Esper; Quintin Pan; Rodney L Dunn; Hero K Hussain; Thomas Chenevert; George J Brewer; Sofia D Merajver Journal: Clin Cancer Res Date: 2003-05 Impact factor: 12.531
Authors: Quintin Pan; Celina G Kleer; Kenneth L van Golen; Jennifer Irani; Kristen M Bottema; Carlos Bias; Magda De Carvalho; Enrique A Mesri; Diane M Robins; Robert D Dick; George J Brewer; Sofia D Merajver Journal: Cancer Res Date: 2002-09-01 Impact factor: 12.701
Authors: Elaina M Gartner; Kent A Griffith; Quintin Pan; George J Brewer; Gwen F Henja; Sofia D Merajver; Mark M Zalupski Journal: Invest New Drugs Date: 2008-08-20 Impact factor: 3.850
Authors: Kenneth L van Golen; LiWei Bao; George J Brewer; Kenneth J Pienta; Jeffrey M Kamradt; Donna L Livant; Sofia D Merajver Journal: Neoplasia Date: 2002 Sep-Oct Impact factor: 5.715
Authors: Ji Young Yoo; Jason Pradarelli; Amy Haseley; Jeffrey Wojton; Azeem Kaka; Anna Bratasz; Christopher A Alvarez-Breckenridge; Jun-Ge Yu; Kimerly Powell; Andrew P Mazar; Theodoros N Teknos; E Antonio Chiocca; Joseph C Glorioso; Matthew Old; Balveen Kaur Journal: Clin Cancer Res Date: 2012-07-02 Impact factor: 12.531
Authors: Eva J Ge; Ashley I Bush; Angela Casini; Paul A Cobine; Justin R Cross; Gina M DeNicola; Q Ping Dou; Katherine J Franz; Vishal M Gohil; Sanjeev Gupta; Stephen G Kaler; Svetlana Lutsenko; Vivek Mittal; Michael J Petris; Roman Polishchuk; Martina Ralle; Michael L Schilsky; Nicholas K Tonks; Linda T Vahdat; Linda Van Aelst; Dan Xi; Peng Yuan; Donita C Brady; Christopher J Chang Journal: Nat Rev Cancer Date: 2021-11-11 Impact factor: 69.800
Authors: Ying L Liu; Cecilie Liv Bager; Nicholas Willumsen; Divya Ramchandani; Naomi Kornhauser; Lu Ling; Marta Cobham; Eleni Andreopoulou; Tessa Cigler; Anne Moore; Dayle LaPolla; Veronica Fitzpatrick; Maureen Ward; J David Warren; Claudia Fischbach; Vivek Mittal; Linda T Vahdat Journal: NPJ Breast Cancer Date: 2021-08-23
Authors: S Jain; J Cohen; M M Ward; N Kornhauser; E Chuang; T Cigler; A Moore; D Donovan; C Lam; M V Cobham; S Schneider; S M Hurtado Rúa; S Benkert; C Mathijsen Greenwood; R Zelkowitz; J D Warren; M E Lane; V Mittal; S Rafii; L T Vahdat Journal: Ann Oncol Date: 2013-02-13 Impact factor: 32.976
Authors: Divya Ramchandani; Mirela Berisa; Diamile A Tavarez; Zhuoning Li; Matthew Miele; Yang Bai; Sharrell B Lee; Yi Ban; Noah Dephoure; Ronald C Hendrickson; Suzanne M Cloonan; Dingcheng Gao; Justin R Cross; Linda T Vahdat; Vivek Mittal Journal: Nat Commun Date: 2021-12-15 Impact factor: 14.919